News about "Clinical Trials"

Australia Approves MINJUVI (tafasitamab) for Relapsed or Refractory Follicular Lymphoma

Australia approves MINJUVI (tafasitamab) with rituximab and lenalidomide, the first chemo-free dual-targeted therapy for relapsed follicular lymphoma.

Clinical Trials | 24/04/2026 | By News Bureau

Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer

Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.

Clinical Trials | 23/04/2026 | By News Bureau |  117

AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial

AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.

Clinical Trials | 21/04/2026 | By News Bureau |  101

OS Therapies files patent for immune-response biomarker linked to cancer immunotherapy

New data from the Phase IIb trial of OST-HER2 shows distinct immune signatures tied to improved survival outcomes, supporting accelerated approval discussions with global regulators.

Clinical Trials | 20/04/2026 | By News Bureau

UK Accelerates Clinical Trials, Slashing Set-Up Time to Boost Patient Access

Government-backed reforms and Euro 137 million investment cut trial start times significantly, enabling faster access to innovative treatments through the National Health Service.

Clinical Trials | 17/04/2026 | By News Bureau

NHS Speeds Up Clinical Trials, Accelerating Patient Access to New Treatments

The Government-backed reforms and Euro 137 million investment cut trial set-up times, strengthening the UK’s position as a global leader in clinical research and innovation.

Clinical Trials | 17/04/2026 | By News Bureau

Abbisko's Irpagratinib Secures EMA Orphan Drug Tag for Liver Cancer

European regulator grants rare disease designation to FGFR4 inhibitor, boosting its clinical development and commercial prospects in hepatocellular carcinoma.

Clinical Trials | 01/04/2026 | By News Bureau

Eisai and Nuvation Bio Secure EMA Validation for Taletrectinib in Lung Cancer

EU regulator begins review of next-generation targeted therapy for advanced ROS1-positive non-small cell lung cancer.

Clinical Trials | 30/03/2026 | By News Bureau |  136

GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer

Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.

Clinical Trials | 24/03/2026 | By News Bureau |  126

GenomOncology Partners with WeTrials to Accelerate Clinical Trial Access for CNS Cancer Patients

GenomOncology and WeTrials collaborate to streamline clinical trial enrollment for Central Nervous System Cancer patients, integrating genomic reports with AI-driven patient engagement tools through expanded partnership with Belay Diagnostics.

Clinical Trials | 11/03/2026 | By News Bureau |  111